Market Overview

UPDATE: MLV & Co Downgrades Uroplasty to Hold on Slowing Growth, Competitive Concerns

Share:
Related UPI
Stocks Hitting 52-Week Lows
Stocks Hitting 52-Week Lows

MLV & Co downgraded Uroplasty (NASDAQ: UPI) from Buy to Hold and announced a $3.00 price target.

MLV & Co noted, "Given our expectations for low growth over the next year and the recent approval of two competitive products for OAB from companies with much greater marketing prowess (and budgets) than Uroplasty, we no longer have sufficient visibility to project when the company may reach profitability. Further, we believe lessthan-positive market sentiment and a lack of any meaningful nearterm catalysts will continue to weigh heavily on the shares."

Uroplasty closed at $2.74 on Monday.

Latest Ratings for UPI

DateFirmActionFromTo
Jan 2015Roth CapitalDowngradesBuyNeutral
Jan 2014Dougherty & CompanyReinstatesBuy
May 2013JMP SecuritiesUpgradesMarket PerformMarket Outperform

View More Analyst Ratings for UPI
View the Latest Analyst Ratings

Posted-In: MLV & CoAnalyst Color Downgrades Analyst Ratings

 

Related Articles (UPI)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content